Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Gilead Sciences, Inc. logo
GILD
Gilead Sciences, Inc.
20:00:01
123.76 $
0.0000 (%0.00)
Previous Close: 125.45
Day Low₺122.43
Day High₺126.39
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

GILD: Gilead Sciences, Inc. Financials

Gilead Sciences, Inc. Income Statement

Total revenue
Net income
Gross margin TTM
78.83%
Operating margin TTM
39.74%
Net profit margin TTM
28.9%
Return on investment TTM
37.49%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue29,442,000,00028,754,000,00027,116,000,00027,281,000,000
Operating income11,701,000,0001,662,000,0007,605,000,0007,330,000,000
Net income8,510,000,000480,000,0005,665,000,0004,592,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue29,442,000,00028,754,000,00027,116,000,00027,281,000,000
Cost of revenue6,234,000,0006,251,000,0006,498,000,0005,657,000,000
Gross profit23,208,000,00022,503,000,00020,618,000,00021,624,000,000
Research and development expenses5,799,000,0005,907,000,0005,718,000,0004,977,000,000
General and administrative expenses2,186,000,0002,638,000,0002,818,000,0004,895,000,000
Selling and marketing expenses3,522,000,0003,453,000,0003,272,000,000778,000,000
Selling, general and administrative expenses5,708,000,0006,091,000,0006,090,000,0005,673,000,000
Other expenses08,843,000,0001,205,000,0003,644,000,000
Operating expenses11,507,000,00020,841,000,00013,013,000,00014,294,000,000
Cost and expenses17,741,000,00027,092,000,00019,511,000,00019,951,000,000
Net interest income-675,000,000-696,000,000-568,000,000-829,000,000
Interest income349,000,000281,000,000376,000,000106,000,000
Interest expense1,024,000,000977,000,000944,000,000935,000,000
Depreciation and amortization2,760,000,0002,767,000,0002,693,000,0002,103,000,000
EBITDA13,580,000,0004,434,000,00010,496,000,0008,852,000,000
EBIT10,820,000,0001,667,000,0007,803,000,0006,749,000,000
Non-operating income (excl. interest)881,000,000-5,000,000-198,000,000581,000,000
Operating income11,701,000,0001,662,000,0007,605,000,0007,330,000,000
Total other income/expenses (net)-1,905,000,000-972,000,000-746,000,000-1,516,000,000
Income before tax9,796,000,000690,000,0006,859,000,0005,814,000,000
Income tax expense1,286,000,000211,000,0001,247,000,0001,248,000,000
Net income from continuing operations8,510,000,000479,000,0005,612,000,0004,566,000,000
Net income from discontinued operations0000
Other adjustments to net income01,000,0001,000,0000
Net income8,510,000,000480,000,0005,665,000,0004,592,000,000
Net income deductions0000
Bottom line net income8,510,000,000480,000,0005,665,000,0004,592,000,000
EPS70.3854
Diluted EPS70.3854
Weighted average shares outstanding1,244,000,0001,247,000,0001,248,000,0001,255,000,000
Weighted average diluted shares outstanding1,255,000,0001,255,000,0001,258,000,0001,262,000,000

Gilead Sciences, Inc. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
24,592,000,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets59,023,000,00058,995,000,00062,125,000,00063,171,000,000
Total liabilities36,405,000,00039,749,000,00039,376,000,00041,962,000,000
Total equity22,702,000,00019,330,000,00022,833,000,00021,240,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents7,564,000,0009,991,000,0006,085,000,0005,412,000,000
Short-term investments3,041,000,0001,577,000,0001,179,000,000973,000,000
Cash and short-term investments10,605,000,00011,568,000,0007,264,000,0006,385,000,000
Net receivables4,913,000,0004,420,000,0004,660,000,0004,777,000,000
Accounts receivable4,913,000,0004,420,000,0004,660,000,0004,777,000,000
Other receivables0000
Inventory4,368,000,0001,710,000,0001,787,000,0001,507,000,000
Prepaid expenses0480,000,00001,774,000,000
Other current assets0995,000,0002,374,000,0000
Total current assets19,886,000,00019,173,000,00016,085,000,00014,443,000,000
Property, plant and equipment (net)5,606,000,0005,414,000,0005,317,000,0005,475,000,000
Goodwill8,314,000,0008,314,000,0008,314,000,0008,314,000,000
Intangible assets16,978,000,00019,948,000,00026,454,000,00028,893,000,000
Goodwill and intangible assets25,292,000,00028,262,000,00034,768,000,00037,207,000,000
Long-term investments001,163,000,0001,245,000,000
Tax assets02,378,000,00000
Other non-current assets8,239,000,0003,769,000,0004,792,000,0004,800,000,000
Total non-current assets39,137,000,00039,823,000,00046,040,000,00048,727,000,000
Other assets0-1,000,00001,000,000
Total assets59,023,000,00058,995,000,00062,125,000,00063,171,000,000
Total payables02,479,000,0001,758,000,0001,864,000,000
Accounts payable0833,000,000550,000,000905,000,000
Other payables01,646,000,0001,208,000,000959,000,000
Accrued expenses03,892,000,0003,802,000,0003,479,000,000
Short-term debt01,815,000,0001,798,000,0002,273,000,000
Capital lease obligations (current)0000
Tax payables0830,000,0001,208,000,000959,000,000
Deferred revenue0000
Other current liabilities11,813,000,0003,818,000,0003,922,000,0003,622,000,000
Total current liabilities11,813,000,00012,004,000,00011,280,000,00011,238,000,000
Long-term debt24,592,000,00024,896,000,00023,189,000,00022,957,000,000
Capital lease obligations (non-current)0000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)0724,000,0001,588,000,0002,673,000,000
Other non-current liabilities02,125,000,0003,319,000,0005,094,000,000
Total non-current liabilities24,592,000,00027,745,000,00028,096,000,00030,724,000,000
Other liabilities0000
Capital lease obligations0000
Total liabilities36,405,000,00039,749,000,00039,376,000,00041,962,000,000
Treasury stock0000
Preferred stock0000
Common stock1,000,0001,000,0001,000,0001,000,000
Retained earnings13,730,000,00011,497,000,00016,304,000,00015,687,000,000
Additional paid-in capital8,932,000,0007,700,000,0006,500,000,0005,550,000,000
Accumulated other comprehensive income/loss39,000,000132,000,00028,000,0002,000,000
Other stockholders' equity0000
Total stockholders' equity22,702,000,00019,330,000,00022,833,000,00021,240,000,000
Total equity22,618,000,00019,246,000,00022,749,000,00021,209,000,000
Minority interest-84,000,000-84,000,000-84,000,000-31,000,000
Total liabilities and total equity59,023,000,00058,995,000,00062,125,000,00063,171,000,000
Total investments3,041,000,0001,577,000,0002,342,000,0002,218,000,000
Total debt24,592,000,00026,711,000,00024,987,000,00025,230,000,000
Net debt17,028,000,00016,720,000,00018,902,000,00019,818,000,000

Gilead Sciences, Inc. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations10,019,000,00010,828,000,0008,006,000,0009,072,000,000
Cash from investing-4,793,000,000-3,449,000,000-2,265,000,000-2,466,000,000
Cash from financing-7,745,000,000-3,433,000,000-5,125,000,000-6,469,000,000
Net change in cash-2,427,000,0003,906,000,000673,000,00074,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income8,510,000,000480,000,0005,665,000,0004,592,000,000
Depreciation and amortization2,760,000,0002,767,000,0002,693,000,0002,103,000,000
Deferred income tax160,000,000-1,844,000,000-962,000,000-1,552,000,000
Stock-based compensation894,000,000835,000,000766,000,000644,000,000
Change in working capital-3,948,000,000-880,000,000-2,303,000,000-1,763,000,000
Accounts receivable-367,000,000139,000,000157,000,000-406,000,000
Inventory-1,036,000,000-426,000,000-842,000,000-310,000,000
Accounts payable-132,000,000290,000,000-347,000,000226,000,000
Other working capital-2,413,000,000-883,000,000-1,271,000,000-1,273,000,000
Other non-cash items1,643,000,0009,470,000,0002,147,000,0005,048,000,000
Net cash from operating activities10,019,000,00010,828,000,0008,006,000,0009,072,000,000
Investments in property, plant and equipment-563,000,000-523,000,000-585,000,000-728,000,000
Acquisitions (net)-1,070,000,000-4,840,000,000-1,152,000,000-1,797,000,000
Purchases of investments-4,072,000,000-736,000,000-2,372,000,000-1,942,000,000
Sales/maturities of investments909,000,0002,592,000,0001,844,000,0002,002,000,000
Other investing activities3,000,00058,000,0000-1,000,000
Net cash from investing activities-4,793,000,000-3,449,000,000-2,265,000,000-2,466,000,000
Net debt issuance-1,788,000,0001,494,000,000-270,000,000-1,500,000,000
Long-term net debt issuance-1,788,000,0001,494,000,000-270,000,000-1,500,000,000
Short-term net debt issuance0000
Net stock issuance-1,514,000,000-728,000,000-768,000,000-1,087,000,000
Net common stock issuance-1,514,000,000-728,000,000-768,000,000-1,087,000,000
Common stock issuance408,000,000422,000,000232,000,000309,000,000
Common stock repurchased-1,922,000,000-1,150,000,000-1,000,000,000-1,396,000,000
Net preferred stock issuance0000
Net dividends paid-4,003,000,000-3,918,000,000-3,809,000,000-3,709,000,000
Common dividends paid-4,003,000,000-3,918,000,000-3,809,000,000-3,709,000,000
Preferred dividends paid0000
Other financing activities-440,000,000-281,000,000-278,000,000-173,000,000
Net cash from financing activities-7,745,000,000-3,433,000,000-5,125,000,000-6,469,000,000
Effect of FX changes on cash92,000,000-40,000,00057,000,000-63,000,000
Net change in cash-2,427,000,0003,906,000,000673,000,00074,000,000
Cash at end of period7,564,000,0009,991,000,0006,085,000,0005,412,000,000
Cash at beginning of period9,991,000,0006,085,000,0005,412,000,0005,338,000,000
Operating cash flow10,019,000,00010,828,000,0008,006,000,0009,072,000,000
Capital expenditure-563,000,000-523,000,000-585,000,000-728,000,000
Free cash flow9,456,000,00010,305,000,0007,421,000,0008,344,000,000
Income taxes paid02,779,000,0003,990,000,0003,136,000,000
Interest paid0951,000,000891,000,000907,000,000